Cargando…
Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is a haematological malignancy representing the most diagnosed non-Hodgkin’s lymphoma (NHL) subtype. Despite the approved chemotherapies available in clinics, some patients still suffer from side effects and relapsed disease. Recently, studies have reported the...
Autores principales: | Wang, Sicong, Clapper, Erin, Tonissen, Kathryn F., Di Trapani, Giovanna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952695/ https://www.ncbi.nlm.nih.gov/pubmed/36830087 http://dx.doi.org/10.3390/antiox12020529 |
Ejemplares similares
-
To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors
por: Busker, Sander, et al.
Publicado: (2020) -
Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020) -
TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport
por: Zhang, Yushuo, et al.
Publicado: (2017) -
MiR-23-TrxR1 as a novel molecular axis in skeletal muscle differentiation
por: Mercatelli, Neri, et al.
Publicado: (2017) -
Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity
por: Lei, Hong, et al.
Publicado: (2018)